Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Stuart A. Morgan"'
Autor:
Carlos A. Penno, Stuart A. Morgan, Anna Vuorinen, Daniela Schuster, Gareth G. Lavery, Alex Odermatt
Publikováno v:
Journal of Lipid Research, Vol 54, Iss 10, Pp 2874-2883 (2013)
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) mediates glucocorticoid activation and is currently considered as therapeutic target to treat metabolic diseases; however, biomarkers to assess its activity in vivo are still lacking. Recent in vit
Externí odkaz:
https://doaj.org/article/96982beff9f44610b4f3ca9c6468e8d3
Autor:
Stuart Zola-Morgan, Mark Kritchevsky
Publikováno v:
Spatial Cognition ISBN: 9781315785462
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c59b28a6d3252fb5c78726f784835dde
https://doi.org/10.4324/9781315785462-22
https://doi.org/10.4324/9781315785462-22
Autor:
Zaki K Hassan-Smith, Carl Jenkinson, David J Smith, Ivan Hernandez, Stuart A Morgan, Nicola J Crabtree, Neil J Gittoes, Brian G Keevil, Paul M Stewart, Martin Hewison
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0170665 (2017)
Age-associated decline in muscle function represents a significant public health burden. Vitamin D-deficiency is also prevalent in aging subjects, and has been linked to loss of muscle mass and strength (sarcopenia), but the precise role of specific
Externí odkaz:
https://doaj.org/article/292b545db1ba400eb583e4542813c297
Autor:
Hanafy, Khalid A., Stuart, R. Morgan, Khandji, Alexander G., Connolly, E. Sander, Badjatia, Neeraj, Mayer, Stephan A., Schindler, Christian
Publikováno v:
In Journal of Clinical Neuroscience 2010 17(7):853-856
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f536dbb4d326babc4988ce32f28405db
https://doi.org/10.1530/endoabs.77.p198
https://doi.org/10.1530/endoabs.77.p198
Publikováno v:
In Neurosurgery Clinics of North America 2009 20(1):111-120
Autor:
Edward O. List, Gareth G. Lavery, Stuart A. Morgan, John J. Kopchick, Paul M. Stewart, Darlene E. Berryman
Publikováno v:
Growth Hormone & IGF Research. 62:101440
Patients with growth hormone deficiency (GHD) have many clinical features in common with Cushing's syndrome (glucocorticoid excess) - notably visceral obesity, insulin resistance, muscle myopathy and increased vascular mortality. Within key metabolic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51587b196aa1f8c3106d7acd40459dce
https://doi.org/10.1016/j.ghir.2021.101440
https://doi.org/10.1016/j.ghir.2021.101440
Autor:
Stuart A. Morgan
Publikováno v:
Pope Eugenius III (1145–1153). :305-320
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12fcd9c82cc555081f95a81d3ec9bdf8
https://doi.org/10.1017/9789048537204.013
https://doi.org/10.1017/9789048537204.013
Autor:
Laura L Gathercole, Stuart A Morgan, Iwona J Bujalska, David Hauton, Paul M Stewart, Jeremy W Tomlinson
Publikováno v:
PLoS ONE, Vol 6, Iss 10, p e26223 (2011)
Patients with glucocorticoid (GC) excess, Cushing's syndrome, develop a classic phenotype characterized by central obesity and insulin resistance. GCs are known to increase the release of fatty acids from adipose, by stimulating lipolysis, however, t
Externí odkaz:
https://doaj.org/article/66eb4965a0194e279a30d6d9c3d451a5
Autor:
Ariana Dela Cruz, Carolyn L. Cummins, Jane Mitchell, Rucha Patel, Jasmine Williams-Dautovich, Ricky Tsai, Keertika Yogendirarajah, Marc D. Grynpas, Stuart A Morgan
Publikováno v:
JBMR Plus. 1:46-57
Glucocorticoids (GCs) have unparalleled anti-inflammatory and immunosuppressive properties, which accounts for their widespread prescription and use. Unfortunately, a limitation to GC therapy is a wide range of negative side effects including Cushing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86025f7c9b4536ab2da9cee1389ab319
https://doi.org/10.1002/jbm4.10009
https://doi.org/10.1002/jbm4.10009